Mutations in IDH1 and IDH2 induce epigenetic and transcriptional reprogramming, and differentiation bias and promote the development of a number of malignancies 99, 100 including but not limited to chondrosarcoma, AML 101, 102, cholangiocarcinoma 103, prostate cancers 104, angioimmunoblastic T-cell lymphomas 105, myeloid neoplasia 106. This evidence concerns the gene IDH1 and acute myeloid leukemia.